Hotline: 86-023-62505954
 
 
R&D About us
Contact Us
/ contact us
If you want to consult products, call us:
TEL:
86-023-62505954
FAX:
86-023-62512066
E-mail:
cpri@cpri.com.cn

CRPI pipeline of drug discovery

 

TA

Project

Regis-

tration

classi-

fication

MOA

Indication

Description

  Status

Pre-

clinical

IND

Clinical

  Trial

NDA

I

II

III

 

CNS

Rasa-

giline

trans-

dermal

patch

II

MAO-B

inhibitor

Parkinson

(1)first

sustained

release

formulation

of

Rasagiline

(2) market

exclusivity

(3) once

every 3

days,good

compliance.

 Innovation drug R&D

Tumor

targeted

therapy

1

1

Cellular

stress

responsive

inhibitor

Triplene-

gative

breast

cancer

First-

in-class

 Innovation drug R&D

2

1

BTK

inhibitor

B cell

associated

lymphoma

Me-better

Innovation drug R&D

3

1

PARP

inhibitor

Ovarian

cancer

Me-better

Innovation drug R&D

4

1

Cell

metabolic

inhibitor

Cancer

First-

in-class

 Innovation drug R&D

Tumor

immune

therapy

5

1

Inhibitor

containing

PD-L1

Caner

Small

molecular,

First-

in-class

 Innovation drug R&D

6

1

Immune

escape

inhibitor

Caner

Small

molecular,

First-

in-class

 Innovation drug R&D

 

 Contact Us
No.565 · NanAnDistrict · ChongQing
Tel: 86-023-62505954
86-023062505956
E-mail:cpri@cpri.com.cn
Copyright ©2005 - 2013 Chongqing Pharmaceutical Research Institute
犀牛云提供企业云服务